Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.

The British journal of dermatology - 1 Nov 2012

Anforth R M, Blumetti T C M P, Kefford R F, Sharma R, Scolyer R A, Kossard S, Long G V, Fernandez-Peñas P

Abstract excerpt

BACKGROUND: Inhibitors of mutant BRAF are emerging as standard of care in patients with metastatic melanoma carrying relevant oncogenic mutations. Cutaneous reactions are frequent and significant. We conducted a systematic prospective dermatological review of all patients enrolled at a single ins...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Imidazoles
Share to Keratinocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Share to Skin Diseases

Share to Skin Neoplasms

Source

Identifiers

PMID: 22804352
DOI: 10.1111/j.1365-2133.2012.11155.x

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22804352-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.PMID 22804352Read ↗

Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation.Semantic proximity Read ↗

Dermatological adverse events from BRAF inhibitors: a growing problem.Semantic proximity Read ↗

Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.Semantic proximity Read ↗

Dermatologic adverse events associated with targeted therapies for melanoma.Semantic proximity Read ↗

Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset.Semantic proximity Read ↗

Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.Semantic proximity Read ↗

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.Semantic proximity Read ↗

Dabrafenib therapy for advanced melanoma.Semantic proximity Read ↗

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.Semantic proximity Read ↗

Dabrafenib for the treatment of melanoma.Semantic proximity Read ↗

Mutational Analysis of BRAF Inhibitor-Associated Squamoproliferative Lesions.Semantic proximity Read ↗

A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.